Your browser is no longer supported. Please, upgrade your browser.
AKTX [NASD]
Akari Therapeutics, Plc
Index- P/E- EPS (ttm)-0.48 Insider Own28.49% Shs Outstand38.47M Perf Week0.11%
Market Cap67.39M Forward P/E- EPS next Y-0.01 Insider Trans0.00% Shs Float24.66M Perf Month-1.73%
Income-15.60M PEG- EPS next Q0.00 Inst Own19.60% Short Float0.19% Perf Quarter4.29%
Sales- P/S- EPS this Y41.20% Inst Trans- Short Ratio0.44 Perf Half Y-25.76%
Book/sh0.04 P/B42.50 EPS next Y- ROA-152.00% Target Price- Perf Year1.19%
Cash/sh0.10 P/C17.73 EPS next 5Y- ROE-315.00% 52W Range1.42 - 4.21 Perf YTD-8.11%
Dividend- P/FCF- EPS past 5Y36.70% ROI- 52W High-59.62% Beta1.27
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low19.72% ATR0.09
Employees9 Current Ratio1.50 Sales Q/Q- Oper. Margin- RSI (14)51.04 Volatility6.08% 5.47%
OptionableNo Debt/Eq0.00 EPS Q/Q54.40% Profit Margin- Rel Volume0.51 Prev Close1.74
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume104.41K Price1.70
Recom2.00 SMA201.99% SMA50-0.64% SMA200-20.23% Volume53,035 Change-2.30%
Jan-04-19Upgrade B. Riley FBR Neutral → Buy $2.50 → $3
Feb-08-18Initiated B. Riley FBR, Inc. Neutral $3
Sep-22-17Upgrade William Blair Mkt Perform → Outperform
May-31-17Upgrade Chardan Capital Markets Sell → Neutral $6
Apr-17-17Reiterated Chardan Capital Markets Sell $6.50 → $5
Jul-11-16Initiated Chardan Capital Markets Sell $5
Oct-26-21 08:00AM  
Oct-25-21 08:30AM  
Sep-22-21 09:00AM  
08:30AM  
Sep-10-21 08:30AM  
Sep-07-21 07:00AM  
Jul-07-21 09:15AM  
Jun-29-21 04:01PM  
Apr-28-21 10:25AM  
08:00AM  
Apr-22-21 07:30AM  
Apr-20-21 06:40PM  
Apr-12-21 12:48PM  
10:16AM  
Mar-04-21 08:30AM  
Feb-25-21 01:41PM  
09:07AM  
Feb-01-21 11:26PM  
09:29AM  
Jan-06-21 09:32AM  
Dec-11-20 09:00AM  
08:55AM  
Dec-03-20 10:00AM  
Nov-30-20 11:35PM  
Oct-27-20 09:00AM  
Oct-06-20 08:30AM  
Sep-29-20 09:30AM  
Sep-10-20 08:00AM  
Sep-02-20 06:19AM  
Sep-01-20 08:30AM  
Aug-31-20 07:00AM  
Aug-12-20 08:23AM  
Jul-01-20 09:16AM  
09:15AM  
Jun-25-20 11:23AM  
May-29-20 07:00AM  
May-21-20 11:32AM  
May-04-20 07:30AM  
May-01-20 07:00AM  
Mar-31-20 08:00AM  
Mar-04-20 08:52AM  
Feb-21-20 07:46AM  
Feb-20-20 05:34PM  
Jan-27-20 08:58AM  
Jan-10-20 09:30AM  
Dec-23-19 08:45AM  
Dec-02-19 08:30AM  
Nov-18-19 06:09AM  
Nov-04-19 08:33AM  
Oct-14-19 08:37AM  
Oct-10-19 08:45AM  
07:31AM  
Oct-06-19 05:15PM  
Sep-19-19 06:54AM  
Sep-18-19 08:00AM  
Sep-16-19 10:29AM  
Sep-13-19 08:00AM  
Sep-04-19 10:02AM  
Sep-03-19 07:00AM  
Sep-02-19 09:17AM  
Aug-30-19 12:51PM  
11:39AM  
10:54AM  
07:27AM  
07:00AM  
Aug-29-19 08:06AM  
Aug-15-19 11:55AM  
Aug-14-19 12:27PM  
08:58AM  
08:00AM  
Aug-09-19 08:30AM  
Jul-31-19 09:57AM  
Jul-17-19 03:00PM  
Jul-04-19 08:35AM  
Jun-28-19 09:22AM  
08:45AM  
Jun-21-19 11:05AM  
Jun-20-19 09:35AM  
Jun-19-19 11:24AM  
07:39AM  
May-29-19 07:45AM  
Apr-29-19 07:30AM  
Apr-26-19 08:48AM  
Apr-24-19 08:09AM  
Apr-23-19 04:01PM  
02:05PM  
11:04AM  
08:30AM  
Mar-27-19 04:15PM  
Mar-18-19 02:30PM  
Mar-14-19 10:06AM  
07:47AM  
Mar-13-19 02:35PM  
10:35AM  
08:30AM  
Feb-21-19 08:30AM  
Feb-04-19 12:45PM  
Jan-29-19 11:10AM  
Dec-26-18 11:19AM  
Nov-30-18 04:05PM  
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barre syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.